Genitourinary system, Prostate adenoma
Best Scan Methods for Better Prostate Health Now
Mar
Prostate health is a critical aspect of men’s overall well-being, particularly as they age. With the advent of advanced scanning technologies, detecting and monitoring prostate issues has become more precise and efficient. However, navigating the various scan methods available can be overwhelming for patients and healthcare providers alike.
In this comprehensive article, we will explore the best scan methods for better prostate health, delving into their advantages, limitations, and suitability for different patient profiles. By providing evidence-based insights and expert opinions, we aim to empower readers with the knowledge necessary to make informed decisions about their prostate health management.
Prostate Health Fundamentals
The prostate gland, a small organ located below the bladder in men, plays a crucial role in reproductive health. As men age, the prostate can become susceptible to various conditions that may impact their quality of life. Understanding the anatomy and function of the prostate is essential for recognizing potential issues and taking proactive steps towards better prostate health.
Anatomy and Function of the Prostate Gland
The prostate gland is about the size of a walnut and surrounds the urethra, the tube that carries urine from the bladder out of the body. Its primary function is to produce and secrete fluid that nourishes and protects sperm during ejaculation[1]. The prostate also helps control the flow of urine through the urethra.
Common Prostate Health Issues
Two of the most common prostate health concerns are benign prostatic hyperplasia (BPH) and prostate cancer. BPH is a non-cancerous enlargement of the prostate that can cause urinary symptoms such as frequent urination, weak urine stream, and difficulty starting or stopping urination[2]. Prostate cancer, on the other hand, is a malignant growth in the prostate gland that can spread to other parts of the body if left untreated.
Importance of Early Detection and Monitoring
Early detection of prostate problems is crucial for effective treatment and management. Regular prostate health screenings, such as the prostate-specific antigen (PSA) test and digital rectal exam (DRE), can help identify issues in their early stages when treatment is most successful[3]. Monitoring prostate health over time can also help track changes and detect any abnormalities that may require further investigation.
Risk Factors for Prostate Problems
Several factors can increase a man’s risk of developing prostate problems, including:
- Age: The risk of prostate issues increases with age, particularly after 50
- Family history: Having a father or brother with prostate cancer doubles a man’s risk
- Race: African American men have a higher risk of prostate cancer than other racial groups
- Diet: A diet high in saturated fat and low in fruits and vegetables may increase prostate cancer risk
By understanding these risk factors, men can take steps to reduce their risk and prioritize prostate health monitoring.
Prostate Cancer Screening Methods
Prostate cancer is one of the most common cancers among men, and early detection is crucial for successful treatment outcomes. Several screening methods are available to help identify prostate cancer in its early stages, allowing for timely intervention and improved prognosis.
Prostate-Specific Antigen (PSA) Test
The PSA test is a blood test that measures the level of prostate-specific antigen, a protein produced by the prostate gland. Elevated PSA levels may indicate the presence of prostate cancer or other prostate conditions[4]. However, PSA levels can also be affected by factors such as age, prostate size, and certain medications, so abnormal results require further evaluation.
Digital Rectal Examination (DRE)
During a DRE, a healthcare provider manually examines the prostate gland through the rectum to check for any abnormalities in size, shape, or texture. While DRE alone is not sufficient for diagnosing prostate cancer, it can help detect tumors that may not be causing elevated PSA levels[5].
Multiparametric Magnetic Resonance Imaging (mpMRI)
Multiparametric MRI is an advanced imaging technique that combines multiple MRI sequences to provide detailed images of the prostate gland. It can help identify suspicious areas that may require further investigation through biopsy. mpMRI is particularly useful for detecting clinically significant prostate cancer and guiding targeted biopsy procedures[6].
Prostate Biopsy
If screening tests suggest the presence of prostate cancer, a biopsy may be recommended. During a prostate biopsy, small tissue samples are collected from the prostate gland for microscopic examination. Traditional biopsy techniques, such as transrectal ultrasound (TRUS) guided biopsy, involve taking random samples from different areas of the prostate. However, newer targeted biopsy approaches, such as MRI-ultrasound fusion biopsy, use mpMRI images to guide the biopsy needle to specific areas of concern, improving the accuracy of cancer detection.
Emerging Screening Techniques
Researchers are continually working on developing new and improved methods for prostate cancer screening. Some emerging techniques include:
- Prostate Health Index (PHI): A blood test that combines three different PSA markers to improve the accuracy of prostate cancer detection
- 4Kscore: Another blood test that evaluates four prostate-specific biomarkers to assess the risk of aggressive prostate cancer
- PCA3 test: A urine test that measures the level of prostate cancer antigen 3 (PCA3), which is overexpressed in prostate cancer cells
As these new techniques undergo further research and validation, they may become valuable tools in the prostate cancer screening arsenal, complementing existing methods and improving early detection rates.
Benign Prostatic Hyperplasia (BPH) Diagnostic Tools
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that can cause bothersome urinary symptoms in men. Accurate diagnosis of BPH is essential for determining the most appropriate treatment plan and ruling out other potential causes of urinary issues, such as prostate cancer.
Medical History and Symptom Assessment
The first step in diagnosing BPH is a thorough evaluation of a patient’s medical history and current symptoms. This may include questions about the frequency and severity of urinary issues, such as difficulty starting or stopping urination, weak urine stream, and increased urination frequency, especially at night[7]. The healthcare provider may also inquire about any medications or supplements the patient is taking, as some can affect urinary function.
Digital Rectal Examination (DRE)
A digital rectal examination allows the healthcare provider to manually assess the size, shape, and consistency of the prostate gland. An enlarged or abnormally shaped prostate may indicate the presence of BPH. However, DRE alone is not sufficient for a definitive BPH diagnosis, as other conditions can cause similar changes in the prostate.
Prostate-Specific Antigen (PSA) Test
Although primarily used as a screening tool for prostate cancer, the PSA test can also provide insight into the presence of BPH. Men with BPH often have elevated PSA levels, although the increase is typically not as high as that seen in prostate cancer[8]. PSA levels can help guide treatment decisions and monitor the progression of BPH over time.
Urinary Flow Test (Uroflowmetry)
Uroflowmetry is a non-invasive test that measures the speed and volume of urine flow. Men with BPH often have a reduced urine flow rate due to the obstruction caused by the enlarged prostate. This test can help assess the severity of BPH and monitor the effectiveness of treatment.
Imaging Tests
In some cases, imaging tests may be used to evaluate the prostate gland and rule out other potential causes of urinary symptoms. These may include:
- Transrectal ultrasound (TRUS): A small probe is inserted into the rectum to create images of the prostate using sound waves
- Magnetic resonance imaging (MRI): Provides detailed images of the prostate and surrounding structures, helping to identify any abnormalities[9]
| Diagnostic Tool | Pros | Cons |
|---|---|---|
| DRE | Quick and inexpensive | Subjective and may miss early BPH |
| PSA Test | Can help monitor BPH progression | May be elevated in other conditions |
| Uroflowmetry | Non-invasive and easy to perform | Results can be affected by other factors |
| Imaging Tests | Provide detailed prostate images | More expensive and time-consuming |
By combining these diagnostic tools, healthcare providers can accurately diagnose BPH and develop personalized treatment plans to manage symptoms and improve patients’ quality of life.
Advancements in Prostate Imaging Technologies
Recent advancements in prostate imaging technologies have revolutionized the way healthcare providers diagnose and monitor prostate conditions. These innovative techniques provide more detailed and accurate images of the prostate gland, enabling earlier detection of abnormalities and more targeted treatment approaches.
Multiparametric Magnetic Resonance Imaging (mpMRI)
Multiparametric MRI has emerged as a powerful tool for prostate imaging, combining multiple MRI sequences to provide comprehensive information about the prostate gland. This technique allows for better visualization of prostate anatomy, tumor location, and extent of disease[10]. mpMRI has significantly improved the accuracy of prostate cancer detection and staging, helping to guide biopsy procedures and treatment planning.
Prostate-Specific Membrane Antigen (PSMA) PET Imaging
PSMA is a protein that is overexpressed on the surface of prostate cancer cells. PSMA PET imaging uses a radioactive tracer that binds specifically to PSMA, allowing for highly sensitive and specific detection of prostate cancer lesions throughout the body. This technique is particularly useful for identifying metastatic disease and recurrent prostate cancer after initial treatment[11].
Ultrasound Elastography
Ultrasound elastography is a technique that measures the stiffness of prostate tissue, as cancerous lesions tend to be harder than normal prostate tissue. This method can be used in combination with traditional transrectal ultrasound (TRUS) to improve the accuracy of prostate cancer detection and guide biopsy procedures. Shear wave elastography and strain elastography are two common types of ultrasound elastography used in prostate imaging[12].
Magnetic Resonance Imaging-Ultrasound Fusion (MRI-US Fusion)
MRI-US fusion is a technique that combines the detailed anatomical information provided by mpMRI with the real-time imaging capabilities of ultrasound. This approach allows for targeted biopsy of suspicious lesions identified on mpMRI, improving the accuracy of prostate cancer diagnosis and reducing the need for repeat biopsies. MRI-US fusion also enables more precise treatment planning, such as focal therapy for localized prostate cancer.
Artificial Intelligence (AI) in Prostate Imaging
AI and machine learning algorithms are being developed to assist in the interpretation of prostate imaging studies, particularly mpMRI. These algorithms can analyze large amounts of imaging data and identify patterns that may be difficult for human radiologists to detect. AI-based tools have the potential to improve the accuracy and efficiency of prostate cancer diagnosis, staging, and treatment response assessment.
As these advanced prostate imaging technologies continue to evolve and become more widely available, they will likely play an increasingly important role in improving outcomes for men with prostate conditions. By providing more accurate and detailed information about the prostate gland, these techniques enable earlier detection, more precise risk stratification, and personalized treatment approaches, ultimately leading to better patient care.
Comparative Analysis of Scan Methods
With the advent of advanced prostate imaging technologies, healthcare providers now have a range of options for visualizing the prostate gland and detecting abnormalities. Each scanning method has its own strengths and limitations, and the choice of technique often depends on factors such as clinical indication, patient characteristics, and available resources. This section will provide a comparative analysis of the most commonly used prostate scan methods.
Transrectal Ultrasound (TRUS)
TRUS is a widely available and relatively inexpensive imaging modality that uses sound waves to create real-time images of the prostate gland. It is typically used to guide prostate biopsy procedures and assess prostate volume. However, TRUS has limited sensitivity for detecting prostate cancer, particularly in the early stages[13]. Additionally, TRUS-guided biopsies may miss some cancers due to the random sampling approach.
Multiparametric Magnetic Resonance Imaging (mpMRI)
mpMRI has emerged as a superior imaging modality for prostate cancer detection and localization compared to TRUS. By combining multiple MRI sequences, mpMRI provides detailed anatomical and functional information about the prostate gland, enabling better visualization of suspicious lesions. Studies have shown that mpMRI has higher sensitivity and specificity for detecting clinically significant prostate cancer compared to TRUS[14]. However, mpMRI is more expensive, time-consuming, and less widely available than TRUS.
Prostate-Specific Membrane Antigen (PSMA) PET Imaging
PSMA PET imaging is a promising new technique for detecting prostate cancer metastases throughout the body. By using a radioactive tracer that binds specifically to PSMA, which is overexpressed on prostate cancer cells, PSMA PET can identify even small metastatic lesions with high sensitivity and specificity. Studies have shown that PSMA PET outperforms conventional imaging modalities, such as computed tomography (CT) and bone scintigraphy, for detecting metastatic prostate cancer[15]. However, PSMA PET is not yet widely available and is primarily used in the setting of recurrent or advanced prostate cancer.
Comparison Table
| Scan Method | Advantages | Disadvantages |
|---|---|---|
| TRUS | Widely available, relatively inexpensive, real-time imaging | Limited sensitivity for detecting prostate cancer, may miss some cancers |
| mpMRI | High sensitivity and specificity for detecting clinically significant prostate cancer, provides detailed anatomical and functional information | More expensive, time-consuming, and less widely available than TRUS |
| PSMA PET | High sensitivity and specificity for detecting metastatic prostate cancer, outperforms conventional imaging modalities | Not yet widely available, primarily used in recurrent or advanced prostate cancer |
In conclusion, each prostate scan method has its own advantages and disadvantages, and the choice of technique should be based on individual patient factors and clinical goals. As imaging technologies continue to advance, healthcare providers will have access to increasingly powerful tools for diagnosing and managing prostate conditions.
Personalized Approach to Prostate Scanning
As our understanding of prostate conditions continues to grow, it has become increasingly clear that a one-size-fits-all approach to prostate scanning is no longer sufficient. Each patient presents with a unique set of risk factors, symptoms, and clinical needs, and the choice of imaging modality should be tailored accordingly. This section will explore the key considerations for developing a personalized approach to prostate scanning.
Risk Stratification
One of the first steps in personalizing prostate scanning is to assess a patient’s individual risk factors for prostate conditions, particularly prostate cancer. Factors such as age, family history, ethnicity, and genetic mutations can all influence a patient’s risk profile[16]. By stratifying patients based on their risk level, healthcare providers can make more informed decisions about the appropriate timing and type of prostate imaging.
Clinical Presentation
The presence and severity of prostate-related symptoms should also be considered when selecting a prostate scanning method. For example, a patient with mild lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) may benefit from a transrectal ultrasound (TRUS) to assess prostate volume and guide treatment decisions. In contrast, a patient with persistently elevated prostate-specific antigen (PSA) levels and a suspicious digital rectal exam (DRE) may require a multiparametric magnetic resonance imaging (mpMRI) to detect and localize prostate cancer.
Patient Preferences and Values
Engaging patients in shared decision-making is critical for developing a personalized approach to prostate scanning. Healthcare providers should discuss the potential benefits, risks, and limitations of each imaging modality with their patients, taking into account individual preferences and values. Some patients may prioritize minimally invasive techniques, while others may place a higher value on diagnostic accuracy. By involving patients in the decision-making process, healthcare providers can foster trust and improve adherence to recommended screening and monitoring protocols[17].
Multidisciplinary Collaboration
Developing a personalized approach to prostate scanning requires close collaboration among healthcare providers from various disciplines, including urology, radiology, oncology, and primary care. Regular multidisciplinary meetings can facilitate the exchange of expertise and ensure that all relevant factors are considered when making imaging decisions. This collaborative approach can also help streamline patient care and reduce unnecessary or duplicative testing[18].
Emerging Technologies and Future Directions
As advanced imaging technologies, such as prostate-specific membrane antigen (PSMA) PET and artificial intelligence (AI)-based tools, become more widely available, they will likely play an increasingly important role in personalized prostate scanning. Healthcare providers should stay up-to-date with the latest research and guidelines to ensure that their patients have access to the most appropriate and innovative imaging modalities.
In conclusion, a personalized approach to prostate scanning that takes into account individual risk factors, clinical presentation, patient preferences, and multidisciplinary collaboration is essential for optimizing outcomes in men with prostate conditions. As our understanding of prostate health continues to evolve, so too must our approach to imaging, ensuring that each patient receives the right scan at the right time for their unique needs.
Prostate Health Management Strategies
While prostate scanning plays a crucial role in diagnosing and monitoring prostate conditions, it is just one component of a comprehensive prostate health management strategy. Adopting a holistic approach that encompasses lifestyle modifications, regular screening, and personalized treatment plans can help men maintain optimal prostate health and improve outcomes in the face of prostate disorders. This section will explore key strategies for managing prostate health.
Lifestyle Modifications
Engaging in healthy lifestyle practices can help reduce the risk of developing prostate conditions and improve overall well-being. Encouraging patients to adopt a balanced diet rich in fruits, vegetables, and whole grains, while limiting processed and high-fat foods, may help reduce inflammation and oxidative stress in the prostate[19]. Regular physical activity, particularly exercises that target the pelvic floor muscles, can improve urinary function and reduce the severity of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Regular Screening
Prostate cancer screening, typically through a combination of prostate-specific antigen (PSA) testing and digital rectal examination (DRE), remains a cornerstone of prostate health management. However, the optimal timing and frequency of screening may vary based on individual risk factors and clinical guidelines. Healthcare providers should engage in shared decision-making with their patients to determine the most appropriate screening protocol, weighing the potential benefits and risks of early detection against the possibility of overdiagnosis and overtreatment[20].
Personalized Treatment Plans
When prostate conditions are diagnosed, healthcare providers should develop personalized treatment plans that take into account the patient’s age, overall health, symptom severity, and personal preferences. For example, men with mild to moderate BPH may benefit from watchful waiting or pharmacological interventions, while those with more severe symptoms may require surgical interventions such as transurethral resection of the prostate (TURP) or minimally invasive procedures like prostatic urethral lift (PUL)[21].
In the case of prostate cancer, treatment options may include active surveillance, radical prostatectomy, radiation therapy, or androgen deprivation therapy (ADT), depending on the stage and aggressiveness of the cancer, as well as patient factors. Engaging patients in the decision-making process and providing clear information about the potential benefits and side effects of each treatment option is essential for ensuring optimal outcomes and quality of life.
Supportive Care and Mental Health
Prostate conditions can have a significant impact on a man’s physical, emotional, and sexual well-being. Healthcare providers should offer supportive care services, such as pelvic floor physical therapy, urinary incontinence management, and sexual health counseling, to help patients cope with the challenges associated with prostate disorders. Addressing the mental health aspects of prostate health is also crucial, as anxiety, depression, and stress can exacerbate symptoms and negatively impact quality of life.
In conclusion, a comprehensive approach to prostate health management that incorporates lifestyle modifications, regular screening, personalized treatment plans, and supportive care is essential for optimizing outcomes and quality of life in men with prostate conditions. By working closely with their healthcare providers and taking an active role in their own health, men can effectively navigate the challenges of prostate disorders and maintain optimal well-being.
Future Directions in Prostate Scanning and Care
As our understanding of prostate health continues to evolve, so too do the technologies and strategies available for diagnosing, monitoring, and treating prostate conditions. This section will explore the exciting future directions in prostate scanning and care, highlighting the potential impact of these advancements on patient outcomes and quality of life.
Artificial Intelligence in Prostate Imaging
Artificial intelligence (AI) is poised to revolutionize prostate imaging by enhancing the accuracy and efficiency of image interpretation. Machine learning algorithms can be trained to analyze multiparametric magnetic resonance imaging (mpMRI) scans, automatically detecting and segmenting suspicious lesions and assisting radiologists in making more precise diagnoses[22]. AI-based tools may also help predict the aggressiveness of prostate cancers, enabling more personalized treatment planning and risk stratification.
Advanced Imaging Techniques
Emerging imaging techniques, such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET) and multiparametric ultrasound (mpUS), are showing promise in improving the detection and characterization of prostate cancers. PSMA PET utilizes radiolabeled ligands that bind specifically to PSMA, a protein overexpressed in prostate cancer cells, allowing for highly sensitive and specific imaging of metastatic lesions[23]. mpUS combines conventional ultrasound with advanced techniques like shear wave elastography and contrast-enhanced ultrasound to provide more detailed information about prostate tissue characteristics and vascularity.
Targeted and Focal Therapies
As prostate imaging becomes more precise, targeted and focal therapies are emerging as potential alternatives to whole-gland treatments for localized prostate cancer. These approaches aim to selectively treat the cancerous tissue while sparing the surrounding healthy prostate, reducing the risk of side effects such as urinary incontinence and erectile dysfunction. Examples of targeted therapies include high-intensity focused ultrasound (HIFU), cryotherapy, and laser ablation[24]. The success of these therapies relies heavily on accurate imaging guidance to ensure complete treatment of the cancerous lesion while minimizing collateral damage.
Precision Medicine and Biomarkers
The future of prostate care lies in precision medicine, which aims to tailor prevention, screening, and treatment strategies to individual patients based on their unique genetic, molecular, and clinical profiles. The development of novel biomarkers, such as circulating tumor cells, exosomes, and microRNAs, may help refine risk stratification, treatment selection, and monitoring of treatment response. Integrating these biomarkers with advanced imaging techniques and AI-based tools could enable a more comprehensive and personalized approach to prostate health management.
Multidisciplinary and Patient-Centered Care
As prostate scanning and treatment options continue to advance, it is crucial to maintain a multidisciplinary and patient-centered approach to care. Collaborations among urologists, radiologists, oncologists, and other healthcare professionals will be essential for optimizing patient outcomes and ensuring seamless coordination of care. Engaging patients and their families in shared decision-making, providing clear and accessible information about the latest advancements in prostate health, and offering comprehensive supportive care services will be key to improving quality of life and patient satisfaction.
In conclusion, the future of prostate scanning and care is filled with exciting possibilities, from AI-powered imaging analysis to targeted therapies and precision medicine approaches. By harnessing these advancements and maintaining a patient-centered focus, healthcare providers can continue to push the boundaries of what is possible in prostate health management, ultimately improving outcomes and quality of life for men worldwide.
Frequently Asked Questions
The most common type of prostate scanning is transrectal ultrasound (TRUS). TRUS is a relatively simple, widely available, and cost-effective method that uses sound waves to create images of the prostate gland. It is often used for initial prostate assessments, guiding biopsies, and monitoring prostate conditions.
The frequency of prostate scanning depends on various factors, such as age, family history, and individual risk factors. Generally, men should discuss prostate cancer screening with their healthcare provider starting at age 50, or earlier if they have a higher risk of developing prostate cancer. The optimal timing and frequency of scanning will be determined based on a personalized assessment of each patient’s needs and risk profile.
Most prostate scanning methods, such as transrectal ultrasound and multiparametric MRI, are generally well-tolerated and cause minimal discomfort. However, some patients may experience slight discomfort or pressure during the procedure, particularly if a transrectal approach is used. If a biopsy is performed during the scan, patients may experience brief pain or discomfort. Healthcare providers can offer guidance on pain management and what to expect during and after the procedure.
Prostate scanning methods are generally safe, but like any medical procedure, they carry some risks. Transrectal ultrasound and biopsy may cause minor bleeding, infection, or discomfort. MRI scans may not be suitable for patients with certain implants or claustrophobia. However, serious complications are rare, and the benefits of early detection and accurate diagnosis often outweigh the potential risks. Patients should discuss any concerns with their healthcare provider.
While advanced imaging techniques like multiparametric MRI can provide highly detailed images of the prostate and help identify suspicious lesions, a definitive diagnosis of prostate cancer can only be made through a biopsy. Prostate scanning methods are used to guide biopsies, targeting specific areas of concern for tissue sampling. The biopsy results, along with imaging findings and other clinical factors, help healthcare providers make an accurate diagnosis and develop an appropriate treatment plan.
Yes, adopting a healthy lifestyle can help promote prostate health and reduce the risk of developing prostate conditions. Some key lifestyle changes include maintaining a balanced diet rich in fruits, vegetables, and whole grains, engaging in regular physical activity, maintaining a healthy weight, and managing stress. Specific exercises targeting the pelvic floor muscles may also help improve urinary function and reduce the severity of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
The future of prostate scanning and care is promising, with ongoing advancements in imaging technologies, artificial intelligence, and targeted therapies. Emerging techniques like prostate-specific membrane antigen (PSMA) PET and multiparametric ultrasound are improving the detection and characterization of prostate cancers. AI-based tools are enhancing image interpretation and assisting in personalized treatment planning. Targeted and focal therapies are being developed to selectively treat cancerous tissue while minimizing side effects. As these innovations progress, a multidisciplinary and patient-centered approach to care will remain essential for optimizing outcomes and quality of life for men with prostate conditions.
Reference list
- Smith JK, Patel S, Jones RB. Advances in prostate imaging: A comprehensive review. Urol Clin North Am. 2023;50(2):179-190.
- Bjurlin MA, Carroll PR, Eggener S, et al. Update of the AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020;203(4):706-713.
- Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351.
- Drost FH, Osses D, Nieboer D, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol. 2020;77(1):78-94.
- Stabile A, Giganti F, Emberton M, Moore CM. MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. Prostate Cancer Prostatic Dis. 2018;21(4):473-487.
- Zhen L, Liu X, Yegang C, et al. Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: A systematic review and meta-analysis. BMC Cancer. 2019;19(1):1244.
- Manfredi M, Mele F, Garnelli M, et al. Multiparametric prostate MRI: technical conduct, standardized report and clinical use. Minerva Urol Nefrol. 2018;70(1):9-21.
- Bonekamp D, Schelb P, Wiesenfarth M, et al. Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values. Radiology. 2018;289(1):128-137.
- Harvey H, Morgan V, Fromageau J, O’Shea T, Bamber J, deSouza NM. Ultrasound Shear Wave Elastography of the Normal Prostate: Interobserver Reproducibility and Comparison with Functional Magnetic Resonance Tissue Characteristics. Ultrason Imaging. 2018;40(3):158-170.
- Schoots IG. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? Transl Androl Urol. 2018;7(1):70-82.
- Valerio M, Cerantola Y, Eggener SE, et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017;71(1):17-34.
- Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100-109.
- Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-1777.
- Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382(10):917-928.
- Pepe P, Garufi A, Priolo GD, et al. Multiparametric MRI/TRUS fusion prostate biopsy: Advantages of a transperineal approach. Anticancer Res. 2017;37(6):3291-3294.
- Rhudd A, McDonald J, Emberton M, Kasivisvanathan V. The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naïve men. Curr Opin Urol. 2017;27(5):488-494.
- Falagario UG, Jambor I, Lantz A, et al. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). Eur Urol Oncol. 2020;3(5):664-670.
- Oishi M, Shin T, Ohe C, et al. Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer? J Urol. 2019;201(2):268-277.
- Kinsella N, Helleman J, Bruinsma S, et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol. 2018;7(1):83-97.
- Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243-262.
- Lam TBL, MacLennan S, Willemse PM, et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019;76(6):790-813.
- Bardou D, Routier E, Gadeano De Kermadec F, et al. Artificial Intelligence in Prostate MRI Diagnosis: The Way to Go. Medicina (Kaunas). 2021;57(7):676.
- Hofman MS, Lawrentschuk N, Francis RJ, et al.Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216.
- Alongi P, Mazzola R, Zattoni F, et al. Advances in prostate cancer imaging and therapy: clinical perspectives for prostate-specific membrane antigen and more. Nucl Med Commun. 2021;42(8):833-843.
